DR.Wu Skincare Co Ltd (6523) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of DR.Wu Skincare Co Ltd stock TWD 107, price TWD 79.80, upside +33.7%, quality 81 out of 100. Rating: undervalued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 45.26 TWD – 160.00 TWD · fair‑value band 76.00 TWD – 145.17 TWD · the 79.80 TWD price screens below the 106.73 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow DR.Wu Skincare Co in your weekly email
Every Wednesday you see whether DR.Wu Skincare Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Dr. Wu Skincare Co., Ltd. engages in the research, development, production, wholesale, and retail of cosmetics and skincare products in Taiwan and internationally.
Show moreShow less
The company offers makeup removers/cleansers, toners, serums, lotions/creams/gels, masks, UV/DD creams, and eye care products, as well as key repair and body care products. It also provides health products/beverages.
The company also provides products for sensitive skin, dry skin, acne and pores, blackheads, dull and spotty skin, and signs of aging. Dr. Wu Skincare Co., Ltd. was incorporated in 2003 and is based in Taipei, Taiwan.
Stock analysis
DR.Wu Skincare Co Ltd (6523) currently trades at 79.80 TWD, while our model-based Fair Value estimate is 106.73 TWD, implying the stock looks roughly 25% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 136.98 TWD per share, and 15 of the 25 models we run sit above the 79.80 TWD price.
Bear case: the Asset-Based group reads lowest at 20.67 TWD, and 10 of the 25 models stay below the price. Data coverage for this calculation is high.
Scenario range: 76.00 TWD (bear) to 145.17 TWD (bull), the price of 79.80 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 81/100 (high quality), in the Consumer Defensive sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
DR.Wu Skincare Co Ltd reported revenue of 1.2B TWD in FY2025 versus 1.1B TWD in FY2021, a compound +1.4%/yr. Reported net income was 350M TWD in FY2025, compounding +4.3%/yr from FY2021.
Key figures
Market cap 3.6B TWD (≈ $109M) Micro · P/E ratio 12.1 · P/S ratio 3.35 · EPS (TTM) 6.60 TWD · Dividend yield 10.0% · Net margin 27.7% · Return on equity 22.1% · Return on assets (EBIT) 25.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 79 out of 100 (medium confidence).
What moves the price
The share trades about 32% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −26% fair-value upside, at 34%, 6523 screens cheaper than that median.
Fair Value models
Bear76.00 TWDFair Value 106.73 TWDBull145.17 TWD
Price 79.80 TWD · Upside +33.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.82/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−5.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.8%
Start year 2020 (pandemic). Over 10 years: +3.0% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+13.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.4%
Dividend (yield on the price)10.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.3.4% vs 3.0%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.104% → 37%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−5.8%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about −7.3% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 229 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score81 · Top 25%
Fair Value upside+33.7% · Above median
Profitability
Return on equity (12 months)22.1% · Top 25%
Return on assets22.0% · Top 25%
Net margin (12 months)27.7% · Top 25%
Operating margin (12 months)13.7% · Above median
Growth and dividend
Revenue growth (quarter YoY)−10.1% · Bottom 25%
Dividend yield (12 months)10.0% · Top 25%
Valuation Multiplesvs Household & Personal Products median · lower = cheaper
P/E (12 months)12.1× · Cheaper than median
P/B2.65× · Pricier than median
P/S (12 months)3.35× · Priciest 25%
Price / free cash flow (fiscal year)10.7× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "DR.Wu Skincare Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/6523
Frequently asked questions
Is DR.Wu Skincare Co Ltd (6523) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 106.73 TWD versus a price of 79.80 TWD, about +34% upside (undervalued).
What is the fair value of 6523?
Our model-based fair value for DR.Wu Skincare Co Ltd is 106.73 TWD (as of Nov 8, 2026), built from audited fundamentals. The current price: 79.80 TWD.
What is the quality score of 6523?
DR.Wu Skincare Co Ltd has a Quality Score of 81/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DR.Wu Skincare Co Ltd (6523)?
Our model-based price target is the fair value of 106.73 TWD (as of Nov 8, 2026) from 25 valuation models. Cautious scenario 76.00 TWD, optimistic scenario 145.17 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the DR.Wu Skincare Co Ltd stock forecast for 2026?
Our models put fair value at 106.73 TWD, about +34% upside versus a price of 79.80 TWD (undervalued). Cautious scenario 76.00 TWD, optimistic scenario 145.17 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of DR.Wu Skincare Co Ltd (6523)?
DR.Wu Skincare Co Ltd reported trailing-twelve-month revenue of about 1.1B TWD (latest available figure, as of Nov 8, 2026).
Does DR.Wu Skincare Co Ltd pay a dividend?
DR.Wu Skincare Co Ltd currently shows a dividend yield of 10.03% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of DR.Wu Skincare Co Ltd (6523) and when is the ex-dividend date?
DR.Wu Skincare Co Ltd pays a dividend of 8.00 TWD per share a year, a dividend yield of 10.0%. The last ex-dividend date was Oct 1, 2026. A dividend has been paid every year since at least 2015. The payout ratio is 121% of earnings. Free cash flow covers the dividend 0.93 times. Our assessment: Payout strained. The dividend exceeds reported earnings (though reported profit is often depressed by one-off charges), and free cash flow only just covers it (or coverage is unknown). Not an emergency, but little room for error.
What growth is priced into DR.Wu Skincare Co Ltd (6523)?
For today's price to be fair in a discounted-cash-flow model, DR.Wu Skincare Co Ltd would have to grow free cash flow by -5.8 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.9 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 6523 use?
Our models discount DR.Wu Skincare Co Ltd at 11.8 %: a base by market capitalisation (micro), damped by beta 0.01, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For DR.Wu Skincare Co Ltd that is -5.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has DR.Wu Skincare Co Ltd (6523) delivered so far?
Over the past 5 years revenue at DR.Wu Skincare Co Ltd grew +8.9 % a year. The price currently implies free-cash-flow growth of -5.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of DR.Wu Skincare Co Ltd (6523) growing?
The median revenue growth in the sector is +3.6 % a year. That is the yardstick for the growth priced into DR.Wu Skincare Co Ltd (-5.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of DR.Wu Skincare Co Ltd (6523)?
The free-cash-flow yield on the price is 9.32 %: that much free cash flow DR.Wu Skincare Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of DR.Wu Skincare Co Ltd (6523)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DR.Wu Skincare Co Ltd it is 106.73 TWD per share (as of Nov 8, 2026), against a price of 79.80 TWD. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is DR.Wu Skincare Co Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 6523 trades below its calculated fair value: price 79.80 TWD, fair value 106.73 TWD, a gap of about +34% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6523?
No. The price is what the market pays today (79.80 TWD); the fair value is what the company's own numbers justify (106.73 TWD). For DR.Wu Skincare Co Ltd the two are 26.93 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is DR.Wu Skincare Co Ltd worth?
The market values DR.Wu Skincare Co Ltd at about 3.6B TWD (market capitalisation, as of Nov 8, 2026). Per share that is 79.80 TWD; our models calculate a fair value of 106.73 TWD per share.
What do the bullish and bearish scenarios say about 6523?
Our models span a range for DR.Wu Skincare Co Ltd: cautious scenario 76.00 TWD, base 106.73 TWD, optimistic 145.17 TWD per share (as of Nov 8, 2026, price 79.80 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6523?
DR.Wu Skincare Co Ltd trades at a price-to-earnings ratio of 12.1 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 106.73 TWD is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 15.7. Other multiples: P/B 2.7, P/S 3.3, EV/EBITDA 10.5.
How solid is the balance sheet of DR.Wu Skincare Co Ltd (6523)?
Balance-sheet figures for DR.Wu Skincare Co Ltd (as of Nov 8, 2026): return on equity 22.1%. They feed the Quality Score of 81/100, which measures business quality independently of the share price.
How far is 6523 from its 52-week high?
DR.Wu Skincare Co Ltd trades at 79.80 TWD, about 32% below its 52-week high of 117.49 TWD and 2% above the low of 78.40 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 106.73 TWD is for.
Which stocks are comparable to DR.Wu Skincare Co Ltd?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, The Estée Lauder Companies Inc, Henkel AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DR.Wu Skincare Co Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price 79.80 TWD, calculated fair value 106.73 TWD (+34%), Quality Score 81/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6523 calculated?
We run DR.Wu Skincare Co Ltd through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 106.73 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. DR.Wu Skincare Co Ltd currently trades 25% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DR.Wu Skincare Co Ltd (6523)?
The closing price on Nov 9, 2026 was 79.80 TWD. Our model-based fair value is 106.73 TWD, about +34% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DR.Wu Skincare Co Ltd right now?
The rarer combination: high quality (81/100) AND below fair value. That earns a closer look rather than a quick verdict. A fairly wide model range (76.00 TWD to 145.17 TWD) leaves room in how you read the outcome.
Where does the earnings growth of DR.Wu Skincare Co Ltd (6523) come from?
Earnings per share at DR.Wu Skincare Co Ltd grew +3.7 % a year from 2013 to 2023. Broken into its drivers: revenue per share +4.2 %, EBIT margin +0.7 %, tax rate −0.3 %, residual (interest, one-offs) −0.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of DR.Wu Skincare Co Ltd
How large is the market capitalisation of DR.Wu Skincare Co Ltd (6523)?
The market capitalisation of DR.Wu Skincare Co Ltd is 3.6B TWD (≈ $109M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DR.Wu Skincare Co Ltd (6523)?
The price-to-sales ratio of DR.Wu Skincare Co Ltd is 3.35 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DR.Wu Skincare Co Ltd (6523)?
Earnings per share at DR.Wu Skincare Co Ltd are 6.60 TWD (price ÷ EPS = P/E 12.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of DR.Wu Skincare Co Ltd (6523)?
The dividend yield of DR.Wu Skincare Co Ltd is 10.0% (payout 121%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of DR.Wu Skincare Co Ltd (6523)?
The net margin of DR.Wu Skincare Co Ltd is 27.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DR.Wu Skincare Co Ltd (6523)?
The return on equity (ROE) of DR.Wu Skincare Co Ltd is 22.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DR.Wu Skincare Co Ltd (6523)?
On an EBIT basis the return on assets of DR.Wu Skincare Co Ltd is 25.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DR.Wu Skincare Co Ltd (6523)?
The operating margin of DR.Wu Skincare Co Ltd is 13.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DR.Wu Skincare Co Ltd (6523)?
Revenue at DR.Wu Skincare Co Ltd is growing −10.1% versus a year earlier (3y avg +8.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at DR.Wu Skincare Co Ltd (6523)?
Earnings per share at DR.Wu Skincare Co Ltd are growing −45.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does DR.Wu Skincare Co Ltd (6523) hold?
DR.Wu Skincare Co Ltd holds more cash than debt, 470M TWD net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch DR.Wu Skincare Co Ltd in the live analysis
One click puts DR.Wu Skincare Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026